Caroline Alleaume1, Marc-Karim Bendiane2,3, Anne-Déborah Bouhnik2, Dominique Rey2,3, Sébastien Cortaredona2, Valérie Seror2, Patrick Peretti-Watel2. 1. Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille University, INSERM, IRD, SESSTIM, 27 Boulevard Jean Moulin, 13385, Marseille cedex 5, France. caroline.alleaume@inserm.fr. 2. Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille University, INSERM, IRD, SESSTIM, 27 Boulevard Jean Moulin, 13385, Marseille cedex 5, France. 3. ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France.
Abstract
PURPOSE: Chronic neuropathic pain (CNP) is more prevalent among cancer survivors than among the general population. This study aims to investigate the role of CNP on job retention among cancer survivors, 5 years after diagnosis. METHODS: In 2015, 2009 individuals diagnosed with cancer in 2010 were interviewed in the French national survey VIe après le CANcer. Logistic regression investigated the relationship between CNP-measured using the seven-item Douleur Neuropathique 4 (DN4) questionnaire-and employment. RESULTS: Nine hundred sixty-nine individuals were aged 18-54 and employed at diagnosis and therefore were included. Eighty-two percent were still employed in 2015, 26% had fewer working hours than before diagnosis, and 55% had the same working hours. Thirty percent reported CNP 5 years after diagnosis. These cancer survivors were less likely to be employed in 2015 than those without CNP and, if employed, were more likely to work fewer hours. After adjustment for gender, medical variables (adverse cancer event, prognosis, chemotherapy, and comorbidities) were found to still significantly affect employment retention in cancer survivors, as well as reporting CNP. CONCLUSION: Improving CNP screening and management is necessary to reduce its impact on cancer survivors' professional lives. IMPLICATIONS FOR CANCER SURVIVORS: Healthcare policy and medical cancer survivor's follow-up must take into account the importance of the substantial impact of CNP on cancer survivors' daily lives. Therefore, in order to ensure greater employment retention for cancer survivors, raising awareness of care providers about diagnosis and management of CNP is needed.
PURPOSE:Chronic neuropathic pain (CNP) is more prevalent among cancer survivors than among the general population. This study aims to investigate the role of CNP on job retention among cancer survivors, 5 years after diagnosis. METHODS: In 2015, 2009 individuals diagnosed with cancer in 2010 were interviewed in the French national survey VIe après le CANcer. Logistic regression investigated the relationship between CNP-measured using the seven-item Douleur Neuropathique 4 (DN4) questionnaire-and employment. RESULTS: Nine hundred sixty-nine individuals were aged 18-54 and employed at diagnosis and therefore were included. Eighty-two percent were still employed in 2015, 26% had fewer working hours than before diagnosis, and 55% had the same working hours. Thirty percent reported CNP 5 years after diagnosis. These cancer survivors were less likely to be employed in 2015 than those without CNP and, if employed, were more likely to work fewer hours. After adjustment for gender, medical variables (adverse cancer event, prognosis, chemotherapy, and comorbidities) were found to still significantly affect employment retention in cancer survivors, as well as reporting CNP. CONCLUSION: Improving CNP screening and management is necessary to reduce its impact on cancer survivors' professional lives. IMPLICATIONS FOR CANCER SURVIVORS: Healthcare policy and medical cancer survivor's follow-up must take into account the importance of the substantial impact of CNP on cancer survivors' daily lives. Therefore, in order to ensure greater employment retention for cancer survivors, raising awareness of care providers about diagnosis and management of CNP is needed.
Entities:
Keywords:
Cancer survivors; Chronic neuropathic pain; Employment retention; VICAN survey
Authors: Bianca Cox; Herman van Oyen; Emmanuelle Cambois; Carol Jagger; Sophie le Roy; Jean-Marie Robine; Isabelle Romieu Journal: Int J Public Health Date: 2009 Impact factor: 3.380
Authors: M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn Journal: Ann Oncol Date: 2007-03-12 Impact factor: 32.976
Authors: C H Paalman; F E van Leeuwen; N K Aaronson; A G E M de Boer; L van de Poll-Franse; H S A Oldenburg; M Schaapveld Journal: Br J Cancer Date: 2016-01-12 Impact factor: 7.640